Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Nursing Students Connect Beyond the Classroom With ONS Resources
    Nursing education
    Nursing Students Connect Beyond the Classroom With ONS Resources
    March 05, 2021
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    COVID-19
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    February 19, 2021
    Celebrate Oncology Nurse Leaders During Black History Month
    ONS Leadership
    Celebrate Oncology Nurse Leaders During Black History Month
    February 03, 2021
    Am I Too Shy to Lead?
    Nurse staffing
    Am I Too Shy to Lead?
    January 29, 2021
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Treatments

    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lower Dose of Cabazitaxel for Prostate Cancer

    On September 14, 2017, the U.S. Food and Drug Administration (FDA) approved a lower dose of cabazitaxel (20 mg/m2 every 3 weeks) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.  Cabazitaxel (25 mg/m2 every 3 weeks) was approved for this indication in 2010.

    September 14, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Copanlisib for Relapsed Follicular Lymphoma

    On September 14, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to copanlisib for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

    September 14, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Biosimilar for Cancer Treatment

    On September 14, 2017, the U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb, Amgen Inc.) as a biosimilar to Avastin (bevacizumab, Genentech Inc.). Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

    September 14, 2017
    Adverse Events From Immunotherapy
    Immunotherapy

    Manage Adverse Events From Immunotherapy and Targeted Therapy for Melanoma

    New targeted and immunotherapy drug approvals have offered improved survival and disease outcomes for patients with melanoma, but the new therapies are also associated with a range of adverse events (AEs) that differ from those associated with chemotherapy. Oncology nurses will need to shift their thinking to best manage those AEs.

    September 12, 2017
    oncology clinical trial nurses impact cancer care
    Oncology clinical trials

    Oncology Nurses Drive Change In Cancer Care With Clinical Trials

    Clinical trials are responsible for discovering new treatments for cancer as well as the continued evolution of standards of care in clinical practice. Nationally, less than 5% of all eligible adult patients with cancer enroll in clinical trials. Additionally, it takes a drug an average of six to eight years from when it is first introduced in trials to become fully available to all patients who could benefit from it.

    September 05, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Gemtuzumab Ozogamicin for CD33-Positive AML

    On September 1, 2017, the U.S. Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and for treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older. Gemtuzumab ozogamicin may be used in combination with daunorubicin and cytarabine for adults with newly-diagnosed AML, or as a stand-alone treatment for certain adult and pediatric patients.

    September 01, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Halts Two Clinical Trials Evaluating Pembrolizumab in Patients With Multiple Myeloma

    On August 31, 2017, based on data from two recently halted clinical trials, the U.S. Food and Drug Administration (FDA) is issuing a statement to inform the public, healthcare professionals, and oncology clinical investigators about the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. Keytruda (pembrolizumab) is not approved for treatment of multiple myeloma.

    August 31, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Tisagenlecleucel for B-cell ALL, Tocilizumab for Cytokine Release Syndrome

    On August 30, 2017, the U.S. Food and Drug Administration granted regular approval to tisagenlecleucel for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

    August 30, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer

    On August 17, 2017, the U.S. Food and Drug Administration granted regular approval to olaparib tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

    August 17, 2017
    Herbs and cancer drugs
    Clinical practice

    Are Your Patients Taking Herbs That May Interact With Their Cancer Drugs?

    Many Americans use dietary supplements, including herbal products, in the belief that they are natural and safe. Patients with cancer use them often to enhance the effects or to reduce the adverse reactions of cancer treatments. However, few herbs have been thoroughly studied in humans. Therefore, their interactions with prescription drugs and the clinical relevance, remain undetermined. These interactions could be pharmacokinetic in nature when an herb alters the absorption, metabolism, or excretion of other drugs, or pharmacodynamic in which it affects the mechanism of action of other drugs when consumed together. Following are a few relevant herb-drug interactions encountered in the oncology setting.

     

    August 15, 2017
    inferior palliative care for minority oncology patients
    End of life (EOL)

    Ethnic Minority Patients May Receive Inferior End-of-Life Care

    According to the results of a study published in the Journal of Clinical Oncology, African American and Hispanic patients with ovarian cancer who lived in Texas were more likely to receive invasive or toxic treatment and be admitted to intensive care in their final month of life than their Caucasian counterparts.

    August 09, 2017
    Childhood Cancer Treatments
    U.S. Food and Drug Administration (FDA)

    Senate Passes Bill to Focus on Childhood Cancer Treatments

    A new bill passed in the U.S. Senate last week will provide measures to ensure that drug companies are developing treatments for children with cancer. The RACE for Children Act is part of the U.S. Food and Drug Administration (FDA) Reauthorization Act of 2017, which aims to speed up the approval process for new treatments and medical devices and is expected to be signed into law by President Trump.

    August 07, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Liposome-Encapsulated Combination of Daunorubicin-Cytarabine for Patients With AML

    On August 3, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine (Vyxeos™, Jazz Pharmaceuticals, Inc.) for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis.

    August 03, 2017
    hematopoietic stem cell transplant care
    Advanced practice nursing (APN)

    Safely Provide Outpatient Care to Patients Receiving Hematopoietic Stem Cell Transplantations

    High-dose chemotherapy with hematopoietic stem cell support is a well-established treatment for many hematologic malignancies. This treatment can be a difficult journey for patients and families. Historically, patients have been treated in a traditional hospital setting in anticipation of severe side effects, including mucositis, febrile neutropenia, thrombocytopenia, and pulmonary, renal, and hepatic complications. Patients can remain profoundly immunosuppressed for months while recovering from transplant. However, better supportive care in recent years has allowed many centers to move all or a portion of their transplant care into an outpatient setting.

    August 03, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Expands Ibrutinib Indications to Chronic GVHD

    On August 2, 2017, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica®, Pharmacyclics LLC) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. This is the first FDA-approved therapy for the treatment of cGVHD.

    August 02, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Nivolumab Accelerated Approval for Colorectal Cancer

    On July 31, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab for the treatment of patients 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

    July 31, 2017
    management of VTE in cancer patients
    Advanced practice nursing (APN)

    Managing VTE in Patients With Cancer

    Venous thromboembolism (VTE) is a potentially life-threatening event characterized by clots that form in the veins, and it is the second-leading cause of death for patients diagnosed with cancer. VTE affects up to 10% of the cancer population, making it essential for oncology providers to understand the associated risk factors and preventative measures. In addition, prompt recognition and treatment for VTE becomes crucial to patient care.

    July 27, 2017
    management of immunotherapy for better quality of life
    Clinical practice

    Management of Immunotherapy-Related Endocrinopathies

    Advanced practice oncology nurses know how complex the care of patients with cancer can be. Every day seems to bring further advancements in the treatment and management of cancer. It can be difficult to keep up with the onslaught of new information, but our patients rely on us to bring them the latest, greatest, and safest treatment options available.

    July 27, 2017
    oncology patient safety in treatments
    Standards

    Using Standards Balances Technology Advancements With Critical Thinking

    Advancements in medical records technology provide safeguards and contribute to overall patient safety. However, consider the following treatment scenarios and how they may present opportunities for error and jeopardize patient safety.

    July 25, 2017
    Immunotherapy Inquiry
    Immunotherapy

    The Case of the Immunotherapy Inquiry, Part II

    You may remember Jay, a 62-year-old man with inoperable stage IIIA non-small cell lung cancer (NSCLC), from the case study in the April 2017 issue of ONS Voice. He was symptomatic with a persistent cough, unintentional weight loss, and fatigue.

    July 18, 2017
    Massage therapy
    Patient quality of life

    Massage Has Therapeutic Value for Patients With Cancer

    An ancient form of bodywork that encompasses hands-on manipulation of muscles and soft tissues, massage increases circulation, reduces muscular tension and promotes relaxation. It also produces emotional and psychological benefits.

    July 14, 2017
    ONS Congress

    Genomic Information Helps Guide Successful Therapies for Each Patient

    The healthcare landscape is changing more rapidly than ever, and daily discoveries in genomics are leading to truly individualized care. During a session at the 42nd Annual Congress in Denver, CO, David Solit, MD, Geoffrey Beene Chair and director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), reviewed cutting-edge genomics science, its role in precision medicine, and innovative genomics programs at his institution. Solit leads a research program that seeks to identify new drug targets using genomic profiling.

    July 03, 2017
    ONS Congress

    Oncology Treatments and Trends Continue to Change Rapidly

    “This has been a historic year in oncology pharmacology,” Rowena Schwartz, PharmD, BCOP, associate professor at the University of Cincinnati, told the audience during a session at the 42nd Annual Congress in Denver, CO. “There were new drugs, yes, but we’re really learning how to use the drugs that we have.”

    July 03, 2017
    ONS Congress

    Combination Drug Offers New Treatment Option for Relapsed Metastatic Colorectal Cancer

    More than 130,000 new cases of colorectal cancers (CRCs) are diagnosed in the United States each year, representing 8% of all new annual cancer cases. The rate of patients with CRC surviving more than five years is 65.1%; however, patients with metastatic disease (mCRC) have a poorer prognosis, with only 13.5% surviving more than years. As many as 40% of patients with mCRC remain candidates for third-line therapy, with some patients requiring up to five lines of therapy because of drug resistance.

    July 01, 2017
    Pam Ginex
    Immunotherapy

    Cultivate Your Immunotherapy Education With ONS Resources

    Cancer centers across the country, especially those in larger medical centers, are seeing many immunotherapy agents in standard care now. Patients are hearing about advancements in immunotherapies, they’re excited by the possibilities, and the U.S. Food and Drug Administration is approving new drugs or indications almost every month. Although many patients still don’t recognize the distinction between standard treatment options and immunotherapy, it’s vital for nurses to stay educated and understand how these treatments work differently from traditional care options.

    June 06, 2017
    immunotherapy for cancer treatment
    Immunotherapy

    How the Evolution of Immunotherapy Will Impact Oncology Nurses

    Immunotherapy is one of the fastest-evolving areas of oncology to date. Previously, it could take years for some cancers to see new treatment options; today, the U.S. Food and Drug Administration is approving new immuno-oncology agents or new indications for those agents every few weeks. It’s a boon and a challenge to medical professionals. On the one hand, potentially life-changing treatments are making way to patients who need them—patients who have exhausted first-line treatments and now have limited options. On the other hand, healthcare professionals may struggle to stay current with the emerging trends, cutting-edge science, and evolving treatment plans for their patients.

    June 01, 2017
    Accelerated Approval to Pembrolizumab
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site Agnostic Indication

    On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda®, Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

    May 23, 2017
    administering IV chemotherapy treatments
    Treatments

    What Special Considerations Are Needed When Setting up IV Chemotherapy?

    No solid research exists regarding IV chemotherapy administration setups, because they can vary greatly based on the regimen, equipment availability, and patient status. Of the utmost importance is that the administration setup ensures chemotherapy is given safely and allows for prompt nursing intervention in the event of an adverse reaction or infiltration.

    May 23, 2017
    Immunotherapy Inquiry
    Immunotherapy

    The Case of the Immunotherapy Inquiry

    Jay is a 62-year-old man with newly diagnosed, stage IIIA (T3, N1), unresectable, non-small cell lung cancer (NSCLC) that tested negative for ALK, EGFR, and KRAS mutations. Additionally, PD-L1 (programed death receptor ligand) expression was less than 30%. Jay is symptomatic with a persistent cough, unintentional weight loss, and fatigue.

    April 18, 2017
    Immunotherapy Agents
    Immunotherapy

    What Oncology Nurses Need to Know About Immunotherapy Agents

    As immunotherapeutic options for cancer treatments continue to grow, oncology nurses need a deeper understanding of the therapies, how they work, and how to manage their side effects, so they can continue to provide the best patient care.

    April 11, 2017
    Treatments

    Two Studies Demonstrate SBRT Improves Survival in NSCLC

    Sterotactic body radiation therapy (SBRT) was found to improve overall survival in two different populations of patients with non-small cell lung cancer (NSCLC), according to two studies presented at the American Society for Radiation Oncology annual meeting.
    December 27, 2016
    Treatments

    CDC, FDA Say Younger Adolescents Need Only Two HPV Vaccine Doses

    In October 2016, the Centers for Disease Control and Prevention (CDC) issued a recommendation that adolescents aged 9–14 need only two doses of the human papillomavirus vaccine at least six months apart, rather than the previously recommended three doses, to achieve immunity.
    December 06, 2016
    Treatments

    Perceived Barriers Affect Nonadherence to Breast Cancer Treatment

    Women with early-stage breast cancer who have more perceived barriers to aromatase inhibitor (AI) treatment are less likely to adhere to their treatment regimens, according to the results of a study published in Cancer.
    November 22, 2016
    Adjuvant therapy

    Gene Expression Helps Predict Benefit From Adjuvant Chemo for Breast Cancer

    Although nearly 60% of all patients with early-stage breast cancer are given adjuvant chemotherapy, only 2%–15% of them receive clinical benefit, according to research published in the 2016 American Society of Clinical Oncology Educational Book.
    October 18, 2016
    Breast cancer

    Why More Women Are Choosing Bilateral Mastectomies

    In just seven years, the rates of women who received prophylactic bilateral mastectomies after a diagnosis of unilateral breast cancer skyrocketed—though many don't require bilateral mastectomy. So what’s causing the increase in unnecessary surgery?
    October 11, 2016
    Breast cancer

    Palbociclib Plus Letrozole Improves Survival in Advanced Breast Cancer

    A study presented at the 2016 ASCO annual meeting confirmed findings that led to the U.S. Food and Drug Administration approval of palbociclib in combination with letrozole for first-line treatment in women with estrogen receptor -positive, HER2-negative advanced breast cancer.
    October 11, 2016
    Patient assistance programs

    Help Your Patients Navigate the Financial Challenges of Cancer

    Every nurse has been in a situation where he or she is staring at a discharge document, thinking, “This patient will need an immense amount of outside support to adhere to this treatment plan.”
    October 04, 2016
    Genetics & genomics

    Thyroid Cancer Treatment’s Changing Landscape Brings New Hope to Patients

    Until 2011, no effective therapeutic options existed for advanced thyroid cancer. However, thanks to clinical studies that have improved the understanding of thyroid cancer’s molecular basis, four kinase inhibitors were approved by the U.S. Food and Drug Administration.
    September 27, 2016
    Immunotherapy

    An Oncology Nursing Overview of New Immune Checkpoint Inhibitors

    Immunotherapy has led to many new cancer treatments over the past several years and continues to offer increased options and better survival for patients. Oncology nurses need to have an understanding of how these therapies work and how to best manage patients’ side effects.
    September 13, 2016
    Immunotherapy

    MABp1 May Be Effective for Metastatic Colorectal Cancer

    A new immunotherapy drug, MABp1, is the first to target interleukin-1 alpha and may be effective in patients with metastatic colorectal cancer. The study results were presented at the World Congress of Gastrointestinal Cancer in Barcelona, Spain.
    September 13, 2016
    Cancer treatments

    Does the Sequence of Chemotherapy and Biotherapy Agents Matter?

    Sequencing of cancer treatment regimens is based on multiple factors, including the pharmacokinetic properties of the agents in the regimen and their effectiveness based on cell-cycle specificity. Because of potential interactions and effects, some regimens have critically important administration sequencing.
    August 18, 2016
    Immunotherapy

    How Can Radiotherapy and Immunotherapy Combine for the Future of Cancer Care?

    Conventional radiation therapies typically use x-rays to deliver radiation treatments to patients with cancer. However, centers around the United States are focusing more on the promise of proton therapy, as well as researching the links between radiation treatments and immunotherapy.
    August 02, 2016
    Interdisciplinary teams

    Alpha, Beta, and Beyond: How Radiation Therapy Is Evolving in Cancer Care

    The field of radiation therapy has come a long way since the introduction of x-rays in 1896. Radiation therapy is now used in nearly 50% of all cancer cases and contributes to 40% of curative treatment. With recent advancements, radiation therapy has grown by leaps and bounds.
    August 02, 2016
    Multiple myeloma

    New Treatments and Insights in Multiple Myeloma

    An interview with Beth Faiman, PhD, CNP, and Kimberly Noonan, NP

    June 03, 2016
    Immunotherapy

    Immunotherapy Is Changing the Future of Cancer Care

    Today, the focus of many groundbreaking cancer therapies has turned inward—to the body’s own immune system. Although using the immune system to fight cancer isn’t a new theory, huge advances in the field of immunotherapy have started to change the landscape of cancer treatment as we know it.
    June 01, 2016
    Immunotherapy

    What’s in Store for the Future of Immunotherapy?

    There are exciting developments in the field of immunotherapy today. We are seeing much higher response rates with some of the newer forms of immunotherapy, and it seems to work in many different types of cancer.
    May 31, 2016
    Immunotherapy

    What Oncology Nurses Need to Know About the Newest Targeted Therapies

    Oncology immunotherapy options have greatly expanded recently, and it is important for oncology nurses to understand what the therapies are, how they work, and who should be receiving them. Rowena Schwartz, PharmD, BCOP, the vice president of clinical content and services at McKesson Specialty Health, discussed the latest treatment information during a session at the 41st Annual Congress in San Antonio, TX.
    April 25, 2016
    Oncology patient with multiple myeloma
    Cancer treatments

    Multiple Myeloma Is Incurable but Treatable

    This content was developed by ONS, Beth Faiman, PhD, CNP, and Kimberly Noonan, NP, and is sponsored by Amgen. Faiman and Noonan received no payment for their participation.

    April 05, 2016
    Test tubes filled with a clear liquid
    Biotherapy

    Biosimilar Treatments Have Practice Implications

    As biosimilars continue to gain popularity in cancer care, healthcare workers should be prepared to see them in their practice. Here’s what you need to know about this newer drug product.
    April 05, 2016
    Oncology patient with her treating nurse
    Oncology health literacy

    Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma

    Few therapies are effective for treating advanced soft tissue sarcoma, so pazopanib quickly became a commonly prescribed therapy once it was approved for STS in April 2012. Although pazopanib is safe and effective, patients must be educated about its administration and side effects.
    March 08, 2016
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Page 4
    • Current page 5
    • Page 6
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲